Furthermore, the expression levels of CXCL9, CXCL10, CXCL11, and their receptor CXCR3, which perform anti-tumor roles in ICI treatment (49), were found to have increased in PTPRD/PTPRT mutant cancer patients. Here, CXCR3 is linked to neoplasm.